A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-10. Anything still debated is marked as such rather than presented as settled.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
The company was co-founded in 1988 by Donald and Susan Sutherland, who sought ice cream that was neither hard packed nor soft-serve. Cold Stone Creamery opened its first store that year in Tempe, Arizona. The original Cold Stone Creamery, store #0001, remains in operation near the same intersection at the southwest corner of McClintock and Southern in Tempe. The store moved from the original location to this location in the early 1990s. The company has maintained the same concept created by Steve Herrell, who founded Steve's Ice Cream. Patrons select a flavor of ice cream and then choose a number of mix-ins to be added to the ice cream. Mix-ins include candies, nuts, brownies and syrups. Cold Stone derives its name from the frozen granite slab that employees use to fold mix-ins into the ice cream. In 1995, Cold Stone Creamery opened its first franchise store in Tempe, Arizona. Shortly after, a second location was opened, in Camarillo, California. Cold Stone Creamery has become the sixth best-selling brand of ice cream in the US. In 2008, Cold Stone opened its first European franchise in Copenhagen, Denmark. Three more stores were later opened in other parts of the country. In January 2006, the company was named the 11th fastest-growing franchise by Entrepreneur magazine. In June 2009, the company opened its first locations in Canada. As of 2012, three stores had opened in Singapore. In 2012, Cold Stone opened its first store in Nigeria, the first in Sub-Saharan Africa.
The dragonless Aemond claims Vhagar, which leads to a fight between Alicent and Rhaenyra's children where Luke slashes one of Aemond's eyes out. They are all brought before Viserys in a mass gathering, where a furious Alicent demands one of Luke's eyes to be taken out as retribution, arguing with Rhaenyra who defends her kids. After Viserys refuses to abide by Alicent's demand, she grabs his Valyrian steel dagger and rushes towards Luke, but is blocked by Rhaenyra. Aemond asserts that the loss of his eye in exchange for gaining a dragon was a fair trade, and Viserys considers the matter settled under those conditions. He also declares that anyone claiming Rhaenyra's children to be bastards will lose their tongue. Viserys reinstates Otto as his Hand (as Lyonel had recently perished in a fire), where he and Alicent conspire to solidify their family's positions at court while Rhaenyra and Daemon unite to counter their influence over the court. Six years later, Viserys' health has greatly declined, as his face is partially disfigured and he is frequently bedridden. Otto and Alicent have de facto control over royal matters, as Viserys frequently drinks milk of the poppy and has declining mental acuity. Corlys' younger brother Vaemond petitions the crown to be named as Corlys' heir instead of Luke, who he accuses of being a bastard. Otto presides over the matter and is inclined to rule against Luke, but a frail Viserys shows up to the throne room to oversee the matter himself, walking to the Iron Throne with great difficulty and support from Daemon.
=== Recreational use === As of 2021, lidocaine is not listed by the World Anti-Doping Agency as a substance whose use is banned in sport. It is used as an adjuvant, adulterant, and diluent to street drugs such as cocaine and heroin. It is one of the three common ingredients in site enhancement oil used by bodybuilders.
April 30: Start of occupation of Trieste by Yugoslav forces, although challenged by the 2nd New Zealand Division under General Freyberg and the city remained part of Italy. Cox said that it was the first major confrontation of the Cold War and was the one corner of Europe where no demarcation line had been agreed upon in advance by the Allies. May 2: The Italian Civil War ends. May 8: Germany surrenders. End of World War II in Europe (V-E Day). July 24: Potsdam Conference - At the Potsdam Conference, Truman informs Stalin that the United States has nuclear weapons. August 6: Atomic bombings of Hiroshima and Nagasaki - Truman follows the advice of Secretary of War Henry L. Stimson and gives permission for the world's first military use of an atomic weapon, against the Japanese city of Hiroshima. August 8: The USSR honors its agreement to declare war on Japan within three months of the victory in Europe, and invades Manchuria. August 9: With no Japanese response to his ultimatums, Truman gives permission for the world's second and last military use of an atomic weapon, against the Japanese city of Nagasaki (Kokura was the original target). August 12: Japanese forces in Korea surrender to Soviet and American armies. August 17: Proclamation of Indonesian Independence - The Dutch East Indies declares its independence from the Dutch. This marked the beginning of the Indonesian National Revolution.
By the late 1940s, the economic wounds from years of redlining and restrictive covenants hurt the standard of living for many African Americans and minorities living in Detroit. With limited housing opportunities and sky-high rents, those living in "red" neighborhoods like Black Bottom and Paradise Valley often had little financial ability to pay for private apartments or housing repairs. Consequences of close-quarter living were exacerbated by an influx of black immigrants during the Great Migration and World War II. The decaying neighborhoods also developed sanitation problems; garbage pickups were rare, and trash littered the street, accelerating the spread of diseases and enticing pests. Perceptions of "urban blight" and a need for "slum clearance" in these areas were fueled especially by (majority white) Detroit city planners, who classified over two-thirds of housing in Paradise Valley as substandard. Detroit Mayor Edward Jeffries put forth a plan for "urban renewal" in Black Bottom and Paradise Valley neighborhoods in 1944. Utilizing eminent domain laws, the government began taking down buildings in the Black Bottom neighborhood in 1949. Local government officials popularized the push for urban renewal in post-World War II Detroit in conjunction with real estate agents and bank owners, who stood to gain from investment in new buildings and wealthier residents.
Sources: en.wikipedia.org
=== Zika outbreak === While Zika has not been reported in India (as of 6 February 2016), on 3 February 2016, Dr Lal PathLabs and other competing pathology labs announced they were preparing Zika test kits. Dr Lal PathLabs reported they plan to sell their kits for Rs 4500 (€60). However, several days later IndiaToday reported: "the Union Ministry of Health pulled up private players, saying they cannot cash in on a public health emergency" and also reported that Dr. Vandana Lal (executive director of Dr Lal PathLabs) stated: "We don't want to talk on this matter. We don't have any tests for Zika virus and we are also not importing any test kits for the same. If at all we plan to do something, we will take the government's prior permission."
== Pseudoverdine == A compound related to pyoverdine, called pseudoverdine (formally known as 3-formylamino-6,7-dihydroxycoumarin) is also produced by some fluorescent Pseudomonads. It is thought that pseudoverdine and pyoverdine may arise from a common precursor, 2,4,5-trihydroxyphenylalanine, which may condense with L-2,4-diaminobutyric acid to initiate pyoverdine production. Pseudoverdine is relatively similar to pyoverdine in its fluorescence and other spectroscopic properties, and its ability to chelate ferric iron, albeit at much lower affinity. Unlike pyoverdine, it is incapable of transporting iron into cells, likely due to the absence of the peptide chain. Another dissimilarity is that pseudoverdine does not appear to be regulated by the same processes as pyoverdine.
=== JCAMP-DX === This format was one of the earliest attempts to supply a standardized file format for data exchange in mass spectrometry. JCAMP-DX was initially developed for infrared spectrometry. JCAMP-DX is an ASCII based format and therefore not very compact even though it includes standards for file compression. JCAMP was officially released in 1988. Together with the American Society for Mass Spectrometry a JCAMP-DX format for mass spectrometry was developed with aim to preserve legacy data.
In 1820, Michael Faraday liquefied ammonia and other gases by using high pressures and low temperatures, and in 1834, Jacob Perkins built the first working vapor-compression refrigeration system in the world. It was a closed-cycle that could operate continuously, as he described in his patent, "I am enabled to use volatile fluids for the purpose of producing the cooling or freezing of fluids, and yet at the same time constantly condensing such volatile fluids, and bringing them again into operation without waste." His prototype system worked although it did not succeed commercially. In 1842, a similar attempt was made by physician John Gorrie, who built a working prototype, but it was a commercial failure. Like many of the medical experts during this time, Gorrie thought too much exposure to tropical heat led to mental and physical degeneration, as well as the spread of diseases such as malaria. He conceived the idea of using his refrigeration system to cool the air for comfort in homes and hospitals to prevent disease. American engineer Alexander Twining took out a British patent in 1850 for a vapour compression system that used ether. The first practical vapour-compression refrigeration system was built by the journalist James Harrison. His 1856 patent was for a vapour-compression system using ether, alcohol, or ammonia. He built a mechanical ice-making machine in 1851 on the banks of the Barwon River at Rocky Point in Geelong, Victoria, and his first commercial ice-making machine followed in 1854.
This new version is designed and optimized for use by high-throughput laboratory automation instruments. In 2017, the company launched LBgard Blood Tubes, which allow collection and preservation of cfDNA for 14 days, and CTCs and WBCs for 4 days, for liquid biopsy and NIPT applications. In 2012, the company began offering custom stabilization services to diagnostic assay manufacturers under the trade name, AssayStable. This service allowed improved manufacturing and stability of diagnostic test kits. After completing several successful contracts with large diagnostic manufacturers, the company launched a related service, PCRstable, that focused specifically on improving stability of PCR-based, molecular diagnostic assays, including those using microfluidic chips and specialized cartridges and cassettes. To facilitate testing and adoption of the company's stabilizers, Biomatrica launched the ReadyDry PCR Stabilizer Screening Kit in 2016.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.